vs
因美纳（ILMN）与Prenetics Global Ltd（PRE）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是Prenetics Global Ltd的257.0倍（$1.1B vs $4.3M）
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
Prenetics是一家总部位于中国香港的健康科学企业，业务辐射美国地区，专注于癌症等疾病的早期筛查、预防与干预诊疗，致力于帮助人们更早发现健康风险，助力提升相关疾病的治疗效果，推动肿瘤等重疾的早防早治，守护公众健康。
ILMN vs PRE — 直观对比
营收规模更大
ILMN
是对方的257.0倍
$4.3M
损益表 — Q4 2025 vs Q3 2023
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $4.3M |
| 净利润 | $186.0M | — |
| 毛利率 | 65.9% | 44.9% |
| 营业利润率 | 15.8% | -396.2% |
| 净利率 | 16.8% | — |
| 营收同比 | -1.6% | — |
| 净利润同比 | 205.7% | — |
| 每股收益（稀释后） | $1.16 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ILMNPRE
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — | ||
| Q4 23 | $1.1B | — | ||
| Q3 23 | $1.2B | $4.3M | ||
| Q2 23 | $1.1B | $4.2M | ||
| Q1 23 | — | $92.0M |
净利润ILMNPRE
| Q4 24 | $186.0M | — | ||
| Q3 24 | $705.0M | — | ||
| Q2 24 | $-2.0B | — | ||
| Q1 24 | $-126.0M | — | ||
| Q4 23 | $-754.0M | — | ||
| Q3 23 | $-234.0M | — | ||
| Q2 23 | $3.0M | — | ||
| Q1 23 | — | — |
毛利率ILMNPRE
| Q4 24 | 65.9% | — | ||
| Q3 24 | 69.0% | — | ||
| Q2 24 | 64.8% | — | ||
| Q1 24 | 62.0% | — | ||
| Q4 23 | 61.1% | — | ||
| Q3 23 | 62.2% | 44.9% | ||
| Q2 23 | 60.3% | 32.5% | ||
| Q1 23 | — | 39.2% |
营业利润率ILMNPRE
| Q4 24 | 15.8% | — | ||
| Q3 24 | 68.6% | — | ||
| Q2 24 | -147.2% | — | ||
| Q1 24 | -10.3% | — | ||
| Q4 23 | -67.4% | — | ||
| Q3 23 | -7.5% | -396.2% | ||
| Q2 23 | -5.9% | -544.7% | ||
| Q1 23 | — | — |
净利率ILMNPRE
| Q4 24 | 16.8% | — | ||
| Q3 24 | 65.3% | — | ||
| Q2 24 | -178.8% | — | ||
| Q1 24 | -11.7% | — | ||
| Q4 23 | -67.4% | — | ||
| Q3 23 | -19.9% | — | ||
| Q2 23 | 0.3% | — | ||
| Q1 23 | — | — |
每股收益（稀释后）ILMNPRE
| Q4 24 | $1.16 | — | ||
| Q3 24 | $4.42 | — | ||
| Q2 24 | $-12.48 | — | ||
| Q1 24 | $-0.79 | — | ||
| Q4 23 | $-4.77 | — | ||
| Q3 23 | $-1.48 | — | ||
| Q2 23 | $0.02 | — | ||
| Q1 23 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | — |
| 总资产 | $6.3B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ILMNPRE
| Q4 24 | $93.0M | — | ||
| Q3 24 | $70.0M | — | ||
| Q2 24 | $74.0M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $6.0M | — | ||
| Q3 23 | $6.0M | — | ||
| Q2 23 | $24.0M | — | ||
| Q1 23 | — | — |
股东权益ILMNPRE
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $5.7B | — | ||
| Q4 23 | $5.9B | — | ||
| Q3 23 | $6.6B | — | ||
| Q2 23 | $6.7B | — | ||
| Q1 23 | — | — |
总资产ILMNPRE
| Q4 24 | $6.3B | — | ||
| Q3 24 | $6.0B | — | ||
| Q2 24 | $6.1B | — | ||
| Q1 24 | $10.0B | — | ||
| Q4 23 | $10.1B | — | ||
| Q3 23 | $11.8B | — | ||
| Q2 23 | $11.8B | — | ||
| Q1 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $364.0M | — |
| 自由现金流经营现金流 - 资本支出 | $335.0M | — |
| 自由现金流率自由现金流/营收 | 30.3% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | 1.96× | — |
| 过去12个月自由现金流最近4个季度 | $709.0M | — |
8季度趋势，按日历期对齐
经营现金流ILMNPRE
| Q4 24 | $364.0M | — | ||
| Q3 24 | $316.0M | — | ||
| Q2 24 | $80.0M | — | ||
| Q1 24 | $77.0M | — | ||
| Q4 23 | $139.0M | — | ||
| Q3 23 | $105.0M | — | ||
| Q2 23 | $10.0M | — | ||
| Q1 23 | — | — |
自由现金流ILMNPRE
| Q4 24 | $335.0M | — | ||
| Q3 24 | $284.0M | — | ||
| Q2 24 | $49.0M | — | ||
| Q1 24 | $41.0M | — | ||
| Q4 23 | $94.0M | — | ||
| Q3 23 | $58.0M | — | ||
| Q2 23 | $-42.0M | — | ||
| Q1 23 | — | — |
自由现金流率ILMNPRE
| Q4 24 | 30.3% | — | ||
| Q3 24 | 26.3% | — | ||
| Q2 24 | 4.4% | — | ||
| Q1 24 | 3.8% | — | ||
| Q4 23 | 8.4% | — | ||
| Q3 23 | 4.9% | — | ||
| Q2 23 | -3.9% | — | ||
| Q1 23 | — | — |
资本支出强度ILMNPRE
| Q4 24 | 2.6% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.3% | — | ||
| Q4 23 | 4.0% | — | ||
| Q3 23 | 4.0% | — | ||
| Q2 23 | 4.8% | — | ||
| Q1 23 | — | — |
现金转化率ILMNPRE
| Q4 24 | 1.96× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 3.33× | — | ||
| Q1 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ILMN
| Sequencing | $1.0B | 91% |
| Microarray | $101.0M | 9% |
| Investee | $7.0M | 1% |
PRE
暂无分部数据
